Edition:
India

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

79.96USD
19 Mar 2019
Change (% chg)

$1.13 (+1.43%)
Prev Close
$78.83
Open
$79.12
Day's High
$80.25
Day's Low
$79.02
Volume
1,817,210
Avg. Vol
1,935,101
52-wk High
$80.25
52-wk Low
$56.81

Latest Key Developments (Source: Significant Developments)

Abbott Announces CE Mark For Alinity M Diagnostics System And Assays
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Abbott Laboratories ::ABBOTT ANNOUNCES CE MARK FOR ALINITY™ M DIAGNOSTICS SYSTEM AND ASSAYS, THE LATEST IN MOLECULAR TECHNOLOGY, TO HELP DELIVER CRITICAL TEST RESULTS AND BENEFITS TO PATIENTS.  Full Article

Abbott Sets Quarterly Dividend Of $0.32 Per Share
Friday, 22 Feb 2019 

Feb 22 (Reuters) - Abbott Laboratories ::SETS QUARTERLY DIVIDEND OF $0.32 PER SHARE.  Full Article

Abbott And Novo Nordisk Partner To Provide Integrated Digital Solution To People With Diabetes Using Insulin
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Abbott Laboratories ::ABBOTT AND NOVO NORDISK ENTER PARTNERSHIP TO PROVIDE INTEGRATED DIGITAL SOLUTION TO PEOPLE WITH DIABETES USING INSULIN.ABBOTT - PARTNERSHIP TO INTEGRATE INSULIN DOSE DATA FROM NOVO NORDISK CONNECTED PENS INTO DIGITAL HEALTH TOOLS COMPATIBLE WITH FREESTYLE LIBRE SYSTEM.  Full Article

Abbott Labs says Received CE Mark For Determine HBsAg 2 Test
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Abbott Laboratories ::RECEIVED CE MARK FOR DETERMINE HBSAG 2 TEST FOR USE WITH SERUM, PLASMA OR WHOLE BLOOD.  Full Article

Abbott Sees FY 2019 Earnings Per Share $1.80 To $1.90 From Continuing Operations
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - Abbott Laboratories ::ABBOTT REPORTS 2018 RESULTS AND ISSUES STRONG FORECAST FOR 2019.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.15 TO $3.25 FROM CONTINUING OPERATIONS.SEES Q1 ADJUSTED EARNINGS PER SHARE $0.60 TO $0.62 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES FY 2019 GAAP EARNINGS PER SHARE $1.80 TO $1.90 FROM CONTINUING OPERATIONS.SEES Q1 2019 GAAP EARNINGS PER SHARE $0.25 TO $0.27 FROM CONTINUING OPERATIONS.Q4 ADJUSTED EARNINGS PER SHARE $0.81 FROM CONTINUING OPERATIONS.Q4 GAAP EARNINGS PER SHARE $0.37 FROM CONTINUING OPERATIONS.Q4 EARNINGS PER SHARE ESTIMATE $0.81 -- REFINITIV IBES DATA.QTRLY TOTAL PEDIATRIC SALES $1,013 MILLION VERSUS $1,000 MILLION REPORTED LAST YEAR.QTRLY SALES OF $7.77 BILLION VERSUS $7.59 BILLION.Q4 REVENUE VIEW $7.82 BILLION -- REFINITIV IBES DATA.FOURTH-QUARTER WORLDWIDE SALES OF $7.8 BILLION INCREASED 2.3 PERCENT ON A REPORTED BASIS AND 6.4 PERCENT ON AN ORGANIC BASIS.ISSUING FULL-YEAR 2019 GUIDANCE FOR ORGANIC SALES GROWTH OF 6.5 TO 7.5 PERCENT.FORECASTS NET SPECIFIED ITEMS FOR FULL YEAR 2019 OF $1.35 PER SHARE.QTRLY TOTAL NUTRITION SALES OF $1,777 MILLION VERSUS $1,784 MILLION REPORTED LAST YEAR.FORECASTS SPECIFIED ITEMS FOR Q1 2019 OF $0.35 PER SHARE.FY2019 EARNINGS PER SHARE VIEW $3.20, REVENUE VIEW $32.15 BILLION -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE VIEW $0.64 -- REFINITIV IBES DATA.QTRLY TOTAL DIAGNOSTICS SALES OF $1,961 MILLION VERSUS $1,906 MILLION REPORTED LAST YEAR.SAYS CO IS "VERY WELL-POSITIONED HEADING INTO 2019".  Full Article

Abbott To Acquire Cephea Valve Technologies, Inc.
Wednesday, 16 Jan 2019 

Jan 16 (Reuters) - Abbott Laboratories ::ABBOTT TO ACQUIRE CEPHEA VALVE TECHNOLOGIES, INC..ABBOTT TO ACQUIRE CEPHEA VALVE TECHNOLOGIES, INC..ABBOTT LABORATORIES - FINANCIAL TERMS WERE NOT DISCLOSED.ABBOTT LABORATORIES - FINANCIAL TERMS WERE NOT DISCLOSED..ABBOTT LABORATORIES - EXERCISED OPTION TO BUY CEPHEA VALVE TECHNOLOGIES, A PRIVATELY HELD MEDICAL DEVICE CO.  Full Article

Abbott Raises Quarterly Dividend 14 Pct To $0.32/Share
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Abbott Laboratories ::RAISES QUARTERLY DIVIDEND 14%, INCREASING PAYOUTS FOR 47 STRAIGHT YEARS.INCREASES QUARTERLY DIVIDEND BY 14 PERCENT TO $0.32PER SHARE.  Full Article

Abbott Laboratories-Entered Into A Five Year Credit Agreement On Nov 30
Saturday, 1 Dec 2018 

Nov 30 (Reuters) - Abbott Laboratories ::ABBOTT LABORATORIES - ENTERED INTO A FIVE YEAR CREDIT AGREEMENT ON NOVEMBER 30.ABBOTT LABORATORIES - REVOLVING CREDIT AGREEMENT PROVIDES ABBOTT WITH THE ABILITY TO BORROW UP TO $5 BILLION ON AN UNSECURED BASIS.ABBOTT LABORATORIES - ANY BORROWINGS UNDER REVOLVING CREDIT AGREEMENT WILL MATURE AND BE PAYABLE ON FIFTH ANNIVERSARY OF EFFECTIVE DATE.ABBOTT LABORATORIES - ABBOTT TERMINATED ALL COMMITMENTS OUTSTANDING UNDER FIVE YEAR CREDIT AGREEMENT, DATED JULY 10, 2014 WITH BANK OF AMERICA.  Full Article

NY A.G. Underwood Announces Settlement With Abbott Labs
Friday, 9 Nov 2018 

Nov 9 (Reuters) - New York Attorney General Barbara Underwood::SETTLEMENT RESOLVING INVESTIGATION INTO ABBOTT LABORATORIES OVER "MISLEADING" MARKETING SURVEYS COMPANY SENT.SAYS SETTLEMENT REQUIRES ABBOTT TO ACCURATELY DISCLOSE PURPOSE FOR WHICH SURVEY INFORMATION IS SOUGHT.SETTLEMENT ALSO REQUIRES ABBOTT TO PAY $50,000 IN COSTS.  Full Article

Abbott's Heartmate 3 Heart Pump Now FDA Approved For Advanced Heart Failure Patients Not Eligible For Heart Transplant
Friday, 19 Oct 2018 

Oct 19 (Reuters) - Abbott Laboratories ::ABBOTT'S HEARTMATE 3 HEART PUMP NOW FDA APPROVED FOR ADVANCED HEART FAILURE PATIENTS NOT ELIGIBLE FOR A HEART TRANSPLANT.  Full Article

MEDIA-Abbott shifts to digital health services in India - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy